UBS Group Reaffirms “Neutral” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “neutral” rating restated by analysts at UBS Group in a research note issued on Friday, MarketBeat Ratings reports. They presently have a GBX 1,940 price target on the stock. UBS Group’s price objective suggests a potential upside of 7.32% from the stock’s current price.

Several other research analysts also recently weighed in on GSK. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research note on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a report on Thursday, January 15th. Berenberg Bank raised their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Thursday, January 8th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of GBX 1,829.17.

GSK Trading Up 0.2%

Shares of GSK opened at GBX 1,807.64 on Friday. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 1,909.73. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The stock has a market capitalization of £72.92 billion, a P/E ratio of 13.59, a PEG ratio of 1.24 and a beta of 0.31. The firm has a fifty day simple moving average of GBX 1,817.89 and a two-hundred day simple moving average of GBX 1,631.79.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Wendy Becker bought 441 shares of GSK stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds bought 1,650 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average price of GBX 1,810 per share, for a total transaction of £29,865. Insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.